Companies
New York-listed Regeneron secures $270 million US Ebola order as African outbreak approaches 10,000 infections
US pharmaceutical company Regeneron has secured an additional $270 million order from the US government for its approved Ebola treatment as a separate strain of the virus spreads across Africa. Regeneron has secured an additional $270 million order from the US government for its Ebola treatment, Inmazeb. The company…
Business Insider AfricaBy Ayodeji Adegboyega
Share
Read the full story
Africa Business Review aggregates and summarises reporting from trusted publishers. The full article is published by Business Insider Africa.
Read at Business Insider Africa →Original headline: “New York-listed Regeneron secures $270 million US Ebola order as African outbreak approaches 10,000 infections”
- Local Markets